1975-52-6Relevant articles and documents
Selective oxidation of substituted xylenes to toluic acids by hypochlorite-Ru system under phase transfer conditions
Sasson, Yoel,Al Quntar, Abed El-Aziz,Zoran, Ami
, p. 73 - 74 (1998)
Instantaneous aqueous extraction of toluic acid salts is the basis for a novel selective process for the oxidation of a single methyl group of various xylenes; aqueous hypochlorite is inert towards methylbenzenes at pH higher than 9.0, however, in the presence of an organic solvent, a Ru catalyst and a phase transfer agent, rapid oxidation to benzoic acids is observed at 25°C.
Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists
Worm, Karin,Weaver, Damian G.,Green, Rosalyn C.,Saeui, Christopher T.,Dulay, Doreen-Marie S.,Barker, William M.,Cassel, Joel A.,Stabley, Gabriel J.,DeHaven, Robert N.,LaBuda, Christopher J.,Koblish, Michael,Brogdon, Bernice L.,Smith, Steven A.,Dolle, Roland E.
scheme or table, p. 5004 - 5008 (2010/03/24)
Recently sulfamoyl benzamides were identified as a novel series of cannabinoid receptor ligands. Replacing the sulfonamide functionality and reversing the original carboxamide bond led to the discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Selective CB2 agonist 31 (Ki = 2.7; CB1/CB2 = 190) displayed robust activity in a rodent model of postoperative pain.
Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
Kung, Pei-Pei,Funk, Lee,Meng, Jerry,Collins, Michael,Zhou, Joe Zhongxiang,Catherine Johnson,Ekker, Anne,Wang, Jeff,Mehta, Pramod,Yin, Min-Jean,Rodgers, Caroline,Davies II, Jay F.,Bayman, Eileen,Smeal, Tod,Maegley, Karen A.,Gehring, Michael R.
supporting information; experimental part, p. 6273 - 6278 (2009/08/15)
Information from X-ray crystal structures were used to optimize the potency of a HTS hit in a Hsp90 competitive binding assay. A class of novel and potent small molecule Hsp90 inhibitors were thereby identified. Enantio-pure compounds 31 and 33 were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC50 values averaging 20 nM.